Business
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026.
About this update from Amgen Inc.
[{"type":"text","content":"Organizational Changes Further Emphasize Integration of Biology and Technology","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026.","length":239,"tagName":"p"},{"type":"text","content":"Reese joined Amgen in 2005 as a clinical development leader in oncology and later served as executive vice president of Research and Development (R&D) from 2018 to 2023. During his tenure, he led approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies and strengthened discovery research capabilities. As inaugural chief technology officer, Reese encouraged the early adoption of technology and artificial intelligence across all facets of the business, in particular R&D.","length":538,"tagName":"p"},{"type":"text","content":""Dave recognized early the impact that advances in biology and technology would have on our industry and helped lead Amgen through that shift," said Robert A. Bradway, chairman and chief executive officer at Amgen. "The capabilities he built position us to advance what we call convergent innovation and strengthen our ability to serve patients in the years ahead."","length":385,"tagName":"p"},{"type":"text","content":"Convergent innovation brings together biology, data science, and advanced technologies such as artificial intelligence to accelerate the discovery and development of new medicines and transform how patients, providers and other partners engage with the health care system. Amgen is evolving its organization to better connect these interactions with how the company operates. To support this, Amgen is making the following changes effective June 1, 2026:","length":454,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"James Bradner, M.D., will serve as executive vice president, Research and Development, Artificial Intelligence and Data. A physician-scientist with expertise at the intersection of biology and technology, Bradner has advanced the use of emerging technologies in biomedical research and brings his experience to this next phase at Amgen.","length":336,"...